Literature DB >> 22798501

20-HETE-producing enzymes are up-regulated in human cancers.

Anna Alexanian1, Bradley Miller, Richard J Roman, Andrey Sorokin.   

Abstract

BACKGROUND: 20-Hydroxyeicosatetraenoic acid (20-HETE), a metabolite of arachidonic acid (AA) produced by the CYP4A and CYP4F enzyme families has been reported to induce mitogenic and angiogenic responses both in vitro and in vivo, and inhibitors of this pathway reduced growth of brain and kidney tumors.
MATERIALS AND METHODS: Real-Time PCR, western blot and immunohistochemistry were used to compare the expression of CYP4A/F mRNA and protein levels in human cancer tissue samples versus normal controls. Liquid chromatography/mass spectrometry analysis (LC-MS/MS) was performed to measure 20-HETE formation in tumor homogenates. Activation of Ras in human proximal tubule epithelial cells (HRPTEC) treated with stable agonist of 20-HETE was measured using a Ras pull-down detection kit.
RESULTS: The expression of CYP4A/4F genes was markedly elevated in thyroid, breast, colon, and ovarian cancer samples in comparison to matched normal tissues. Furthermore, the levels of the CYP4F2 protein and of 20-HETE were higher in ovarian cancer samples compared to normal control tissues. A stable 20-HETE agonist induced activation of the small-GTPase Ras in HRPTEC cells.
CONCLUSION: The present finding of elevated expression of CYP4A/F enzymes in human cancer tissue suggests that 20-HETE inhibitors and antagonists may be useful in the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22798501      PMCID: PMC3601443     

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  17 in total

1.  HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme.

Authors:  N Miyata; K Taniguchi; T Seki; T Ishimoto; M Sato-Watanabe; Y Yasuda; M Doi; S Kametani; Y Tomishima; T Ueki; M Sato; K Kameo
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

Review 2.  Prostaglandins and cancer.

Authors:  D Wang; R N Dubois
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

Review 3.  Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system.

Authors:  Noriyuki Miyata; Richard J Roman
Journal:  J Smooth Muscle Res       Date:  2005-08

4.  Human U251 glioma cell proliferation is suppressed by HET0016 [N-hydroxy-N'-(4-butyl-2-methylphenyl)formamidine], a selective inhibitor of CYP4A.

Authors:  Meng Guo; Richard J Roman; John R Falck; Paul A Edwards; A Guillermo Scicli
Journal:  J Pharmacol Exp Ther       Date:  2005-08-04       Impact factor: 4.030

5.  Cytochrome P450 4A isoform inhibitory profile of N-hydroxy-N'-(4-butyl-2-methylphenyl)-formamidine (HET0016), a selective inhibitor of 20-HETE synthesis.

Authors:  Takayuki Seki; Mong-Heng Wang; Noriyuki Miyata; Michal Laniado-Schwartzman
Journal:  Biol Pharm Bull       Date:  2005-09       Impact factor: 2.233

6.  Inhibitors of cytochrome P450 4A suppress angiogenic responses.

Authors:  Ping Chen; Meng Guo; Dana Wygle; Paul A Edwards; John R Falck; Richard J Roman; A Guillermo Scicli
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

7.  20-HETE agonists and antagonists in the renal circulation.

Authors:  M Alonso-Galicia; J R Falck; K M Reddy; R J Roman
Journal:  Am J Physiol       Date:  1999-11

Review 8.  Eicosanoids and cancer.

Authors:  Dingzhi Wang; Raymond N Dubois
Journal:  Nat Rev Cancer       Date:  2010-02-19       Impact factor: 60.716

9.  Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11.

Authors:  P K Powell; I Wolf; R Jin; J M Lasker
Journal:  J Pharmacol Exp Ther       Date:  1998-06       Impact factor: 4.030

10.  20-Hydroxyeicosatetraenoic acid is formed in response to EGF and is a mitogen in rat proximal tubule.

Authors:  F Lin; A Rios; J R Falck; Y Belosludtsev; M L Schwartzman
Journal:  Am J Physiol       Date:  1995-12
View more
  17 in total

1.  Role of 20-Hydroxyeicosatetraenoic Acid (20-HETE) in Androgen-Mediated Cell Viability in Prostate Cancer Cells.

Authors:  Cecilia Colombero; Daniela Papademetrio; Paula Sacca; Eduardo Mormandi; Elida Alvarez; Susana Nowicki
Journal:  Horm Cancer       Date:  2017-06-21       Impact factor: 3.869

2.  20-HETE Signals Through G-Protein-Coupled Receptor GPR75 (Gq) to Affect Vascular Function and Trigger Hypertension.

Authors:  Victor Garcia; Ankit Gilani; Brian Shkolnik; Varunkumar Pandey; Frank Fan Zhang; Rambabu Dakarapu; Shyam K Gandham; N Rami Reddy; Joan P Graves; Artiom Gruzdev; Darryl C Zeldin; Jorge H Capdevila; John R Falck; Michal Laniado Schwartzman
Journal:  Circ Res       Date:  2017-03-21       Impact factor: 17.367

Review 3.  Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology.

Authors:  Fan Fan; Ying Ge; Wenshan Lv; Matthew R Elliott; Yoshikazu Muroya; Takashi Hirata; George W Booz; Richard J Roman
Journal:  Front Biosci (Landmark Ed)       Date:  2016-06-01

Review 4.  CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid ω-hydroxylase activities.

Authors:  Katheryne Z Edson; Allan E Rettie
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

Review 5.  Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer.

Authors:  Amanda L Johnson; Katheryne Z Edson; Rheem A Totah; Allan E Rettie
Journal:  Adv Pharmacol       Date:  2015-06-27

6.  Expression and Functional Characterization of Breast Cancer-Associated Cytochrome P450 4Z1 in Saccharomyces cerevisiae.

Authors:  Matthew G McDonald; Sutapa Ray; Clara J Amorosi; Katherine A Sitko; John P Kowalski; Lorela Paco; Abhinav Nath; Byron Gallis; Rheem A Totah; Maitreya J Dunham; Douglas M Fowler; Allan E Rettie
Journal:  Drug Metab Dispos       Date:  2017-10-10       Impact factor: 3.922

7.  Vascular characterization of mice with endothelial expression of cytochrome P450 4F2.

Authors:  Jennifer Cheng; Matthew L Edin; Samantha L Hoopes; Hong Li; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Fred B Lih; Victor Garcia; Jafar Sadik B Shaik; Kenneth B Tomer; Gordon P Flake; John R Falck; Craig R Lee; Samuel M Poloyac; Michal L Schwartzman; Darryl C Zeldin
Journal:  FASEB J       Date:  2014-03-25       Impact factor: 5.191

8.  HET0016, a selective inhibitor of 20-HETE synthesis, decreases pro-angiogenic factors and inhibits growth of triple negative breast cancer in mice.

Authors:  Thaiz Ferraz Borin; Debora A P C Zuccari; Bruna V Jardim-Perassi; Lívia C Ferreira; A S M Iskander; Nadimpalli Ravi S Varma; Adarsh Shankar; Austin M Guo; Guillermo Scicli; Ali S Arbab
Journal:  PLoS One       Date:  2014-12-30       Impact factor: 3.240

Review 9.  Cytochrome P450: Implications for human breast cancer.

Authors:  Bin Luo; Dandan Yan; Honglin Yan; Jingping Yuan
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

10.  Targeting 20-HETE producing enzymes in cancer - rationale, pharmacology, and clinical potential.

Authors:  Anna Alexanian; Andrey Sorokin
Journal:  Onco Targets Ther       Date:  2013-03-26       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.